411 related articles for article (PubMed ID: 18030609)
1. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Watanabe Y; Kato H; Araki T
Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609
[TBL] [Abstract][Full Text] [Related]
2. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
[TBL] [Abstract][Full Text] [Related]
3. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Kato H; Kurosaki R; Oki C; Araki T
Brain Res; 2004 Dec; 1030(1):66-73. PubMed ID: 15567338
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice.
Muramatsu Y; Kurosaki R; Mikami T; Michimata M; Matsubara M; Imai Y; Kato H; Itoyama Y; Araki T
Metab Brain Dis; 2002 Sep; 17(3):169-82. PubMed ID: 12322787
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T
Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024
[TBL] [Abstract][Full Text] [Related]
6. Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice.
Oki C; Watanabe Y; Yokoyama H; Shimoda T; Kato H; Araki T
Cell Mol Neurobiol; 2008 May; 28(3):417-30. PubMed ID: 18204968
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
8. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice.
Yokoyama H; Yano R; Aoki E; Kato H; Araki T
Metab Brain Dis; 2008 Sep; 23(3):335-49. PubMed ID: 18648914
[TBL] [Abstract][Full Text] [Related]
10. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
11. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625
[TBL] [Abstract][Full Text] [Related]
12. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
14. Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice.
Himeda T; Watanabe Y; Tounai H; Hayakawa N; Kato H; Araki T
J Neural Transm (Vienna); 2006 Dec; 113(12):1887-94. PubMed ID: 16736245
[TBL] [Abstract][Full Text] [Related]
15. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
16. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
[TBL] [Abstract][Full Text] [Related]
17. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.
Oshikawa T; Kuroiwa H; Yano R; Yokoyama H; Kadoguchi N; Kato H; Araki T
Cell Mol Neurobiol; 2009 Jul; 29(5):769-77. PubMed ID: 19370411
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.
Araki T; Mikami T; Tanji H; Matsubara M; Imai Y; Mizugaki M; Itoyama Y
Eur J Pharm Sci; 2001 Jan; 12(3):231-8. PubMed ID: 11113642
[TBL] [Abstract][Full Text] [Related]
20. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]